Novo Nordisk Pays $1.725 Million to Resolve Claims That its Sales Representatives Paid Pharmacists for Access to Confidential Patient Information

Novo Nordisk, Inc. has entered into a civil settlement agreement with the United States in which it has agreed to pay the United States and several states $1.725 million to resolve allegations that the company caused false or fraudulent claims to be submitted to the Medicaid program in connection with its marketing of the diabetes drugs Novolin, Novolin 70/30, Novolog, and Novolog 70/30.

zone article articles roofcargo